- Home
- CDLR vs MNKD Comparison
CDLR vs MNKD Comparison
Compare CDLR & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDLR
- MNKD
- Stock Information
- Founded
- CDLR 2008
- MNKD 1991
- Country
- CDLR Denmark
- MNKD United States
- Employees
- CDLR N/A
- MNKD N/A
- Industry
- CDLR
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- CDLR
- MNKD Health Care
- Exchange
- CDLR Nasdaq
- MNKD Nasdaq
- Market Cap
- CDLR 1.9B
- MNKD 1.7B
- IPO Year
- CDLR N/A
- MNKD 2004
- Fundamental
- Price
- CDLR $18.90
- MNKD $5.52
- Analyst Decision
- CDLR
- MNKD Strong Buy
- Analyst Count
- CDLR 0
- MNKD 5
- Target Price
- CDLR N/A
- MNKD $10.80
- AVG Volume (30 Days)
- CDLR 90.9K
- MNKD 4.6M
- Earning Date
- CDLR 11-25-2025
- MNKD 11-06-2025
- Dividend Yield
- CDLR N/A
- MNKD N/A
- EPS Growth
- CDLR N/A
- MNKD 149.32
- EPS
- CDLR 0.78
- MNKD 0.11
- Revenue
- CDLR $546,159,718.00
- MNKD $301,736,000.00
- Revenue This Year
- CDLR $143.84
- MNKD $16.36
- Revenue Next Year
- CDLR $66.36
- MNKD $20.34
- P/E Ratio
- CDLR $6.20
- MNKD $50.55
- Revenue Growth
- CDLR 277.89
- MNKD 21.48
- 52 Week Low
- CDLR $17.37
- MNKD $3.38
- 52 Week High
- CDLR $27.86
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- CDLR 32.52
- MNKD 56.43
- Support Level
- CDLR $19.50
- MNKD $5.21
- Resistance Level
- CDLR $20.35
- MNKD $5.90
- Average True Range (ATR)
- CDLR 0.53
- MNKD 0.27
- MACD
- CDLR -0.25
- MNKD -0.03
- Stochastic Oscillator
- CDLR 5.19
- MNKD 66.06
About CDLR Cadeler AS
Cadeler AS is an offshore wind farm vessel contractor. It is engaged in offshore wind farm construction, maintenance, and decommissioning and provides marine and engineering operations to the wind industry, focusing on safety and the environment. The company operates six offshore jack-up wind farm installation vessels. In addition to wind farm installation, these vessels can perform maintenance, construction, decommissioning, and other tasks within the offshore industry.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.